Back Tuberculosis

New WHO Report Finds Tuberculosis More Common than Previously Estimated

The global burden of tuberculosis (TB) may encompass nearly half a million more cases than previously thought, due to better data reporting, according to the World Health Organization's Global Tuberculosis Report 2014, released last week. According to the new report, 9 million people developed TB in 2013 and 1.5 million died from the disease, but new cases and mortality continue to decline. The report will be presented at the Union World Conference on Lung Health taking place this week in Barcelona.

alt

Read more:

ICAAC 2014: IRIS and Risk of Early Death Among HIV+ People with Tuberculosis

People coinfected with HIV and tuberculosis (TB) who go onto develop immune reconstitution inflammatory syndrome (IRIS) while on antiretroviral therapy (ART) have a pre-ART immunological profile that is easily distinguishable from those who are at risk of early mortality despite being treated for both HIV and TB, according to a presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC.

alt

Read more:

TAG Releases 2014 HIV, Hepatitis C, and Tuberculosis Pipeline Report

The Treatment Action Group (TAG) and HIV i-Base this week released the latest edition of their annual Pipeline Report, covering new therapies and related technologies for HIV, hepatitis C, and tuberculosis (TB), in conjunction with the 20th International AIDS Conference taking place this week in Melbourne, Australia.

alt

Read more:

ICAAC 2014: Attempt to Shorten Standard Tuberculosis Treatment Fails in REMoxTB Trial

Two 4-month treatment regimens containing moxifloxacin were less effective than the standard 6-month regimen for drug-sensitive tuberculosis (TB), even though they produced a more rapid decline in bacterial load, according to results from the REMoxTB trial, which were presented in a poster session at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, and published simultaneously in the September 7 New England Journal of Medicine.

alt

Read more:

AIDS 2014: Novel PaMZ Tuberculosis Regimen Could Reduce Treatment Duration

A novel tuberculosis (TB) drug regimen could treat drug-sensitive and some forms of drug-resistant TB far more quickly than current standard therapy, according to findings from a Phase 2b trial presented today at the 20th International AIDS Conference (AIDS 2104) in Melbourne, Australia.

alt

Read more: